Your SlideShare is downloading. ×
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

57

Published on

ResearchMoz include new market research report"Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019: Market Trends, Size, Shares, Growth, Analysis and Forecast" to its huge …

ResearchMoz include new market research report"Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019: Market Trends, Size, Shares, Growth, Analysis and Forecast" to its huge collection of research reports.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
57
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth GBI Research has released the pharma report - “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease. Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer. However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period. Additionally, current market conditions are favorable for new mAbs, with high pricing patterns and weak impact from biosimilar exposure. As a result of this, GBI Research believes the global market has the potential to grow to a value of $766m by 2019. Scope A brief introduction to the two indications, including the disease’s pathogenesis, risk factors, diagnosis and treatment algorithms. In-depth analysis of Herceptin, including analysis of its safety, efficacy, treatment patterns and strengths/weaknesses. A comprehensive review of the pipeline for mAbs in gastric and esophageal cancer, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets. Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action. Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain. Discussion of the drivers and barriers for market growth. Reasons to Buy Understand the unmet need in the treatment of these cancers, the role of Herceptin and the areas of opportunity for other mAbs to enter the market. Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent. Observe the trends in clinical trial duration, size and molecule types across the phases of development and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for mAbs in gastric and esophageal cancers. Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs. Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the market for mAbs in gastric and esophageal cancers. table Of Content Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions
  • 2. 1 Table Of Contents 1.1 List Of Tables 1.2 List Of Figures 2 Introduction 2.1 Symptoms 2.1.1 Early Gastric Cancer 2.1.2 Early Esophageal Cancer 2.1.3 Advanced Gastric Or Esophageal Cancer 2.2 Etiology 2.2.1 Esophageal Cancer 2.2.2 Gastric Cancer 2.3 Epidemiology 2.4 Pathophysiology 2.5 Diagnosis 2.6 Prognosis And Disease Staging 2.7 Treatment Options 2.7.1 Chemotherapy 2.7.2 Targeted Therapies 2.7.3 Treatment Guidelines 2.7.4 Resistance To Pharmacological Therapies 2.8 Gbi Research Report Guidance 3 Monoclonal Antibodies Market In Gastric And Esophageal Cancers To 2019- Marketed Products 3.1 Herceptin (trastuzumab) – Hoffman La Roche 4 Monoclonal Antibodies Market In Gastric And Esophageal Cancers To 2019- Developmental Pipeline 4.1 Gastric Cancer 4.1.1 Overall Pipeline 4.1.2 Molecular Targets 4.1.3 Clinical Trials 4.1.4 Conclusion 4.2 Esophageal Cancer 4.2.1 Overall Pipeline 4.2.2 Molecular Targets 4.2.3 Clinical Trials 4.2.4 Conclusion 4.3 Key Late-stage Pipeline Products 4.3.1 Amg 102 (rilotumumab) – Amgen 4.3.2 Imc-1121b (ramucirumab) – Eli Lilly And Company Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions
  • 3. 4.3.3 Theraloc (nimotuzumab) – Ym Biosciences 4.3.4 Metmab (onartuzumab) - F. Hoffmann-la Roche 4.3.5 Perjeta (pertuzumab) - F. Hoffmann-la Roche 4.3.6 Kadcyla (ado-trastuzumab Emtansine) - F. Hoffmann-la Roche 4.4 Conclusion 5 Monoclonal Antibodies Market In Gastric And Esophageal Cancers To 2019- Market Forecast To 2019 5.1 Gastric Cancer 5.1.1 Global 5.1.2 Us 5.1.3 Canada 5.1.4 Europe 5.1.5 Japan 5.2 Esophageal Cancer 5.2.1 Global 5.2.2 Us 5.2.3 Canada 5.2.4 Europe 5.2.5 Japan 5.3 Drivers And Barriers 5.3.1 Drivers 5.3.2 Barriers 6 Deals And Strategic Consolidations 6.1 Licensing Agreements 6.1.1 Gastric Cancer 6.1.2 Esophageal Cancer 6.2 Co-development Agreements 6.2.1 Gastric Cancer 6.2.2 Esophageal Cancer 7 Appendix 7.1 Market Definitions 7.2 Abbreviations 7.3 References 7.4 All Pipeline Products, By Stage Of Development 7.4.1 Gastric Cancer 7.4.2 Esophageal Cancer 7.5 Tabular Forecast Data 7.5.1 Gastric Cancer Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions
  • 4. 7.5.2 Esophageal Cancer 7.6 Research Methodology 7.6.1 Coverage 7.6.2 Secondary Research 7.6.3 Therapeutic Landscape 7.6.4 Epidemiology-based Forecasting 7.6.5 Market Size By Geography 7.6.6 Geographical Landscape 7.6.7 Pipeline Analysis 7.6.8 Competitive Landscape 7.6.9 Expert Panel Validation 7.7 Contact Us 7.8 Disclaimer ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions

×